{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:43:43Z","timestamp":1773157423290,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T00:00:00Z","timestamp":1225152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s12032-008-9108-5","type":"journal-article","created":{"date-parts":[[2008,10,27]],"date-time":"2008-10-27T16:50:37Z","timestamp":1225126237000},"page":"210-214","source":"Crossref","is-referenced-by-count":17,"title":["Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Jaime","family":"Coronel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucely","family":"Cetina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrna","family":"Candelaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Gonz\u00e1lez-Fierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daimy","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cantu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Due\u00f1as-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,28]]},"reference":[{"key":"9108_CR1","doi-asserted-by":"crossref","unstructured":"Parkin DM, Bray F, Ferlay J. Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2000;55:74\u2013108.","DOI":"10.3322\/canjclin.55.2.74"},{"key":"9108_CR2","doi-asserted-by":"crossref","unstructured":"Candelaria M, Cetina L, de la Garza J, Due\u00f1as-Gonz\u00e1lez A. Clinical implications of gemcitabine in the treatment of cervical cancer. Eur J Cancer Suppl. 2007;5:37\u201343. doi: 10.1016\/S1359-6349(07)70014-9 .","DOI":"10.1016\/S1359-6349(07)70014-9"},{"key":"9108_CR3","doi-asserted-by":"crossref","unstructured":"Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7:419\u201334. doi: 10.1007\/s11912-005-0007-z .","DOI":"10.1007\/s11912-005-0007-z"},{"key":"9108_CR4","doi-asserted-by":"crossref","unstructured":"Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113\u20139. doi: 10.1200\/JCO.2004.04.170 .","DOI":"10.1200\/JCO.2004.04.170"},{"key":"9108_CR5","doi-asserted-by":"crossref","unstructured":"Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Gynecologic oncology group study: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol. 2005;23:4626\u201333. doi: 10.1200\/JCO.2005.10.021 .","DOI":"10.1200\/JCO.2005.10.021"},{"key":"9108_CR6","doi-asserted-by":"crossref","unstructured":"Monk BJ, Sill MW, McMeekin SD, Cohn DE, Ramondetta LM, Boardman CH, et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic oncology group (GOG) study [Abstract]. J Clin Oncol. 2008;26:LBA5504.","DOI":"10.1200\/jco.2008.26.15_suppl.lba5504"},{"key":"9108_CR7","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/jco.2008.26.15_suppl.5529","volume":"26","author":"LB Wenzel","year":"2008","unstructured":"Wenzel LB, Huang H, Cella D, Monk BJ, Sill MW, McMeekin SD, et al. Quality-of-life results of a randomized phase III trial of four cisplatin (Cis) containing doublet combinations in stage IVB cervical carcinoma: a Gynecologic oncology group (GOG) study [abstract]. J Clin Oncol. 2008;26:5529.","journal-title":"J Clin Oncol"},{"key":"9108_CR8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00001813-200111000-00001","volume":"12","author":"DT Rein","year":"2001","unstructured":"Rein DT, Kurbacher CM. The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects. Anticancer Drugs. 2001;12:787\u201395. doi: 10.1097\/00001813-200111000-00001 .","journal-title":"Anticancer Drugs"},{"key":"9108_CR9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00001813-200011000-00008","volume":"11","author":"P Boabang","year":"2000","unstructured":"Boabang P, Kurbacher CM, Kohlhagen H, Waida A, Amo-Takyi BK. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-tumor chemosensitivity assay. Anticancer Drugs. 2000;11:843\u20138. doi: 10.1097\/00001813-200011000-00008 .","journal-title":"Anticancer Drugs"},{"issue":"Suppl 5","key":"9108_CR10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1634\/theoncologist.7-suppl_5-36","volume":"7","author":"JV Fiorica","year":"2002","unstructured":"Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7(Suppl 5):36\u201345. doi: 10.1634\/theoncologist.7-suppl_5-36. .","journal-title":"Oncologist"},{"key":"9108_CR11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.9-1-33","volume":"9","author":"DK Armstrong","year":"2004","unstructured":"Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist. 2004;9:33\u201342. doi: 10.1634\/theoncologist . 9-1-33.","journal-title":"Oncologist"},{"key":"9108_CR12","first-page":"754","volume":"15","author":"K Noda","year":"1996","unstructured":"Noda K, Sasaki H, Yamamoto K, Yamamoto T, Nishimura R, Sugiyama T. Phase II trial of topotecan for cervical cancer of the uterus [Abstract]. J Clin Oncol. 1996;15:754.","journal-title":"J Clin Oncol"},{"key":"9108_CR13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1006\/gyno.2000.5807","volume":"77","author":"A Bookman","year":"2000","unstructured":"Bookman A, Blessing JA, Hanjani P, Herzog TJ, Andersen WA: Topotecan in squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol. 2000;77:446\u20139. doi: 10.1006\/gyno.2000.5807 .","journal-title":"Gynecol Oncol"},{"key":"9108_CR14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1525-1438.2000.010004285.x","volume":"10","author":"NR Abu-Rustum","year":"2000","unstructured":"Abu-Rustum NR, Lee S, Massad LS. Topotecan for recurrent cervical cancer after platinum-based therapy. Int J Gynecol Cancer. 2000;10:285\u20138. doi: 10.1046\/j.1525-1438.2000.010004285.x .","journal-title":"Int J Gynecol Cancer"},{"key":"9108_CR15","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","volume":"16","author":"P Hoskins","year":"1998","unstructured":"Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16:2233\u20137.","journal-title":"J Clin Oncol"},{"key":"9108_CR16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/gyno.2000.5844","volume":"78","author":"PG Rose","year":"2000","unstructured":"Rose PG, Gordon NH, Fusco N, Fluellen L, Rodr\u00edguez M, Ingalls ST, et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol. 2000;78:228\u201334. doi: 10.1006\/gyno.2000.5844 .","journal-title":"Gynecol Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-008-9108-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9108-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:35Z","timestamp":1559442155000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-008-9108-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,28]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9108"],"URL":"https:\/\/doi.org\/10.1007\/s12032-008-9108-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,28]]}}}